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ABSTRACTS INTRODUCTION
International Association for the Study of Lung Cancer
In October 1972, the First International Workshop for Ther-apy of Lung Cancer was held at Airlie House Conference
Center outside Washington D.C. This conference, sponsored
by the National Cancer Institute, drew together an interna-
tional group of individuals from all disciplines of medicine
interested in the problem of lung cancer. The interchange of
ideas among this multi-disciplinary international group was
both productive and stimulating. At the concluding meeting,
held on October 20, 1972, Dr. David T. Carr from the Mayo
Clinic, USA, introduced the idea of forming an international
organization to continue this fruitful exchange of ideas, and
generally enthusiastic support for the concept was voiced by
those present at the workshop.
An organizing committee was formed and Dr. David T.
Carr accepted chairmanship of a committee to prepare a
constitution and bylaws. Dr. Oleg S. Selawry, with the
assistance of Drs. Lawrence Broder and George Higgins from
the Washington V.A. Hospital, USA, and other members of
the organization committee began the slow task of develop-
ment. Questionnaires and applications were sent to a wide
variety of individuals with interest in the problem of lung
cancer throughout the world, as well as to those who had
attended the Airlie meeting. By mid 1974, approximately 250
individuals had accepted membership in the Association and
plans were made to have an organization meeting in conjunc-
tion with the XIth International Cancer Congress, sponsored
by the UICC in Florence, Italy.
On the evening of October 26, 1974, in Florence, Italy,
the first formal organizational meeting was held under the
Chairmanship of Dr. Oleg S. Selawry. Bylaws of the Orga-
nization were discussed and adopted by unanimous vote. Dr.
Clifton Mountain, M.D. Anderson Hospital, Houston, USA,
presented the slate of officers and board of directors with
results of the ballots which had been mailed out prior to the
meeting. This slate of officers was unanimously elected.
A formal meeting of the Executive Committee was held
on December 11, 1974, in Key Biscayne, Florida, and many
subsequent informal meetings and discussions were held
concerning development and goals for the Association. The
Association was incorporated as a non-profit corporation.
Membership certificates were designed, with the now familiar
logo, prepared and mailed to all members. Periodic newslet-
ters were prepared and disseminated to inform membership of
organizational progress. Much of this work was done by Dr.
Lawrence Broder, first Secretary of the Association.
Early in 1976, Dr. Selawry assumed a new position at
the Miami Cancer Center and found it impossible to devote
sufficient time to the developing organization and submitted
his resignation in May of 1976.
In Accordance with the Bylaws, the Vice-President,
David T. Carr, assumed the office of President.
With this slow and somewhat tentative beginning, a
solid foundation for the Organization had been established.
Under the energetic leadership of Dr. Clifton Mountain, plans
were made for the First World Congress on Lung Cancer,
sponsored by IASLC. This highly successful conference was
held in May of 1978, at Hilton Head, South Carolina, with
large attendance by participants from throughout the world.
Contributing greatly to the success of this meeting was Dr.
Ronald Vincent, who served as Chairman of the conference.
Now officers and directors were elected to serve during the
period between 1978–80. During this period, under Dr.
George A. Higgins’ leadership, there was a substantial in-
crease in membership. Newsletters were regularly distributed
and plans were made for the Second World Conference.
Under the chairmanship of Dr. Heine H. Hansen, the
Second World Conference on Lung Cancer was held on June
9 to 13, 1980, in Copenhagen, Denmark, and Malmoe, Swe-
den. Over 1000 participants from throughout the world at-
tended this highly successful conference. At the conclusion of
the meeting, the officers and directors were elected for
1980–82.
Tokyo was chosen at the site of the Third World
Conference on Lung Cancer, to he held May 17 to 20, 1982.
Under the able guidance of Dr. Shichiro Ishikawa, Congress
President, and the energetic assistance of Congress Vice
President, Yoshihiro Hayata, the successful Third World
Conference was attended by over 15000 participants repre-
senting most of the major nations of the world.
Decision was made to hold the International World
Conference on Lung Cancer at three-year intervals instead of
two years. Toronto was selected as the site for the Fourth
International Conference on Lung Cancer with Dr. Ronald
Feld serving as Secretary-General and Dr. Ronald Ginsberg
as Chairman of the Program Committee.
The Fourth International Conference on Lung Cancer
was held in Toronto in August of 1985, had an outstanding
program of scientific content. One thousand participants reg-
istered for the conference, representing 33 nations. During
this conference, some new actions were approved by the
officers and the board of the Association. First, aggressive
development of workshops and conferences to take place
between world conferences; second, the format of a quarterly
journal to be sponsored by the IASLC; and third, authoriza-
tion was given to expand the business office of the association
in Copenhagen, Denmark, in order to improve communica-
tion and develop the journal Lung Cancer. Finally, Interlaken,
Switzerland, was chosen to host the 1988 conference, with
Dr. Rudolf Joss as Secretary-General and Chairman of the
Program Committee.
The Fifth World Conference on Lung Cancer, Inter-
laken 1988, was again very successful. Officers and directors
were elected and Dr. Heine H. Hansen commenced his period
Journal of Thoracic Oncology • Vol. 3, No. 4, Supplement 1, 2008 S1
of presidency. Melbourne, Australia, was chosen as the loca-
tion of the 1991 World Conference, with David R. Ball as
Chairman and Secretary-General.
The Sixth World Conference on Lung Cancer was
attended by 1240 delegates from 47 countries and the first
recipient of the IASLC Merit Award was to be found. It was
decided that the award should be given to a person who had
been an IASLC member for at least 10 years, had manifested
himself/herself at an international level as a person engaged
in the field of lung cancer, either preclinically ore clinically,
and had promoted the activities of the IASLC. It was unan-
imously agreed that the first recipient of the IASLC Merit
Award should be Dr. Clifton Mountain.
Colorado Springs, USA, was chosen as the location for
the 7th World Congress with Dr. Paul A. Bunn, Jr. as
Secretary General. At the same time, Dr. Yoshihiro Hayata
began his period as President, and Dr. Heine H. Hansen was
elected Executive Director for the expanding IASLC Office
located in Copenhagen. New activities were planned with a
series of workshops, now also including Eastern Europe and
South Africa. With the support from the industry, travelling
and educational grants within the Organization were created
for promising young investigators and colleagues from de-
veloping countries.
The Seventh World conference was a gigantic success _
scientifically, socially, and economically. Set in beautiful
Colorado Springs, the meeting was attended by 1347 partic-
ipants from 49 countries. The IASLC Merit Award was
shared by Dr. Y. Shimosato and Dr. N. Bleehen. Seven more
awards were given, including Developing Nations awards
and Young Investigator awards. IASLC Recommendations
on Tobacco Policy were established, and Dr. Paul A. Bunn,
Jr., commenced his period of presidency. Dublin, Ireland,
was chosen as the venue for the 8th World Conference with
Dr. Desmond N. Carney as Secretary General.
After the Colorado meeting several workshops were
held on topics ranging from prevention to tumor biology.
Also, the important and successful central European Lung
Cancer Conferences continued with meetings in Prague,
Czech Republic and Gdansk, Poland.
The 8th World Conference in Dublin took place in
August 1997. Dr. Desmond N. Carney and his staff had put
together an exciting and varied programme of science and
entertainment. With the attendance of 2505 delegates from 63
countries, and a surplus which enabled IASLC to expand its
activities during the next 3-year period, the Dublin meeting
was a truly memorable event in the history if IASLC. The
IASLC Merit Award was given to Dr. Heine H. Hansen,
Copenhagen, in recognition of this longstanding contribution
to the IASLC and the Mary J. Matthews Award was given to
Dr. William D. Travis, Washington DC, for his excellence in
lung cancer pathology.
Between the World Conferences in Dublin and Toyko,
a total of 13 workshops, symposia, and other meetings were
arranged under the auspices of IASLC, and 5 meetings were
arranged under the Educational Programme in India, Thai-
land, China, Brazil and Jordan with speakers from the IASLC
Facility. Under the chairmanship of Dr. Peter Goldstraw, UK,
the IASLC Staging Committee launched in 1999 the cumber-
some work of creating a new staging system for lung cancer
based on a truly international data register.
The 9th World Conference was held in Toyko, Japan in
September, 2000 with Dr. Y. Hayata as the Congress Presi-
dent. A total of 1,130 abstracts were submitted to the Con-
ference, which was attended by 2,135 participants from 64
countries. Among the memorable events were the opening
ceremony, attended by members of the Japanese imperial
family, and the gigantic ball with traditional Japanese per-
formers that made a superb conclusion to the conference. The
IASLC Merit Award was given to Dr. Desmond N. Carne,
Ireland, for his outstanding contribution to the IASLC; the
Mary J. Matthews Award was given to Dr. Y. Shimosato,
Japan, for his life long achievements in the field of pathology,
and the Bristol-Myers Squibb Award was given to Daniel C.
Ihde, U.S.A., for his dedication to lung cancer research and
his support of IASLC and its aims. Dr. Harubumi Kato, Japan
took over the Presidency and Dr. Franses Shepherd, Canada
was chosen as the new President-Elect.
The Board decided on the Tokyo Declaration as an
official IASLC document requesting governments worldwide
to take actions against the alarming rate at which lung cancer
is occurring in both men and women. The Tokyo Declaration
is published in this Directory on page 11.
The first IASLC/CRFA Prevention Fellowship Award
was presented in Tokyo to Dr. Jun Zhang, China and in the
spring of 2001, two more Prevention Fellowship grants were
awarded to Dr. Yunfei Wang, USA and Dr. Fred R. Hirsch,
Denmark. Thanks to the energetic work of the President of
CRFA, Carolyn Aldige, three more grants have been secured.
The IASLC Textbook of Lung Cancer, which was
published in 1999, has now been translated into Chinese
thanks to the efforts of Dr. Li Hou-wen, Shenyang, China.
In 2001, workshops and symposia have been arranged
in Barcelona, Spain; in Prague, Czech Republic; in Reykja-
vik, Iceland, and in Chicago, USA. Under the IASLC Edu-
cational Programme, meetings and courses have been ar-
ranged in Dalian, China; in Istanbul, Turkey; in Bialystok.
Poland and in Beijing, China.
The Vancouver Trade and Convention Centre was the
venue for the 10th World Conference of Lung Cancer held in
August 2003 and chaired by Nevin Murray. There were a
total of 3344 registrants from 77 countries and 1149 abstracts
were submitted. Awards presented by IASLC President Ha-
rubumi Kato included: the IASLC Merit Award to Paul A.
Bunn, Mary Matthews Pathology Award to Adi Gazdar, BMS
IASLC Distinguished Achievement Award to Paul van
Houtte and The IASLC Distinguished Service Award to
Heine H. Hansen. The closing gala dinner hosted 2500
delegates with entertainment by ‘‘Cirque Pacifique’’. The
Vancouver meeting maintained the tradition that IASLC
conferences grow in size and academic content without com-
promise of an atmosphere of international collegiality.
The new International Convention Center of Barcelona,
located in the heart of a new activity area of Barcelona on the
shores of the Mediterranean, was the venue for the 11th
World Conference on Lung Cancer, chaired by Rafael Rosell
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and Laureano Molins. This was the largest World Conference
yet, with a total of 4987 registrants from 92 countries and
1488 submitted abstracts. For the first time, a special Fellows’
Day was scheduled in conjunction with the conference, en-
compassing topics that were appealing and useful to younger
investigators. The main program of the conference included
87 sessions, with lectures given by 175 invited speakers and
almost 500 contributors to the scientific program. IASLC
awards included: the IASLC Merit Award to Harubumi Kato;
the Mary Matthews Award to Elisabeth Brambilla; the
IASLC Joseph Cullen Award to Nigel Gray; and the IASLC
Scientific Award to Thierry LeChevalier. Ten Young Inves-
tigator Awards and ten Developing Nation Awards were also
presented to outstanding delegates. The conference was a
unique occasion for investigators from several disciplines to
share their views on lung cancer research and join forces to
create a useful approach to lung cancer management.
12th World Conference on Lung Cancer. The 12th
IASLC World Conference took place at the COEX Conven-
tion Center in Seoul, Korea on September 2–6, 2007. The
conference theme was ‘‘Let’s Make Lung Cancer History’’.
The conference’s main objectives were to:
Y Provide a forum for a world free of tobacco-related
cancer
Y Provide a multidisciplinary forum to share the advance-
ments in lung cancer prevention, diagnosis and treat-
ment
Y Disseminate scientific advances in lung cancer biology
and pathogenesis into clinical practice
Y Encourage new clinical trials based on recent progress in
molecular studies of lung cancer
Y Support the career development of fellows and junior
faculty in lung cancer
The meeting had 4,769 registered delegates plus 112
accompanying person registrations for a total of 4,881 per-
sons from 84 countries. A total of 1,294 abstracts in eleven
categories were submitted to the 12th World Conference of
Lung Cancer from 68 countries.
Scientific highlights: The program included 4 plenary
sessions (Tobacco or Health; Advances in Staging; Advances
in Management of NSCLC; Presidential Symposium), 20
mini symposia, 24 Meet-the-Professor-Sessions, 21 Educa-
tion Sessions, 2 Highlight of the Day Sessions and 15 Satel-
lite Symposia. Four best abstracts were presented at the
Presidential Symposium. Twenty-eight proffered paper ses-
sions and six Poster Discussions were held and 210 oral papers
and 144 poster discussion papers were presented. During three
general Poster Display Sessions, 724 abstracts were shown.
IASLC Merit Award 2007 was given to Peter Gold-
straw, MD, FRCS in recognition of his scientific and organi-
sational leadership through many years. As a chair of the
IASLC Staging Project since 1998, has lead to the collection
of data over 100,000 cases treated by all modalities across the
globe and it has guaranteed the IASLC a major role in
formulating the 7th edition of the TNM classification for lung
cancer. The Mary Matthews Award 2007 was given to Fred
R. Hirsch, MD, PhD for his outstanding contributions to lung
cancer research. Dr. Hirsch initiated the Pathology Commit-
tee within IASLC in 1983 and he has authored more than 200
scientific publications on lung cancer and is Editor of 10
international textbooks in oncology in general and on lung
cancer in particular. Joseph Cullen Award 2007 was given to
Dr. James L. Mulshine, MD. Dr. Mulshine has been working
with a range of organizations to accelerate the use of high
resolution spiral CT in the quantitative evaluation of drung
response for early lung cancer over the last few years. IASLC
Scientific Award 2007 was given to Dr. Frances Shepherd,
MD, FRCPC. Dr. Shepherd has been instrumental in estab-
lishing Lung Cancer Tumor Banks in order to perform cor-
relative science studies pertaining to lung cancer. Through her
leadership, she has brought together a team of basic and clinical
researchers committed to the evaluation of molecular pathways
in lung cancer. This team is recognized world-wide as one of the
foremost groups of bench to beside research pertaining to lung
cancer. And Young Investigators Awards and Developing
Nations Awards are given to ten junior scientists for each.
Dan Idhe Lectureship, Bob Ginsberg Lectureship and Heine
Hansen Lectureship is given to three abstracts.
Social Events: The opening Ceremony combined wel-
coming addresses from Prime Minister of Korea and IASLC
President with Korean drumming and other traditional musi-
cal performances. The closing gala dinner was held at COEX
Convention Hall. Hanbok (the Korean traditional costume)
Fashion show and musical entertainment, Ballroom Dance
were featured and attracted attention from international del-
egates. It was the time for all the delegates to relax and enjoy
a fusion of Korean and Western foods and entertainment.
Over the 3,000 registrants enjoyed.
One of the worthwhile achievements of the 12th WCLC
is the revision to the Tobacco Declaration. At the 12th
WCLC, IASLC added an article of ‘‘In order to help achieve
its goal of eliminating lung cancer, IASLC requests govern-
ment to initiate legislative action for ultimate elimination of
manufacture and sales of tobacco products’’.
The 13th World Lung Cancer Conference will be held
in San Francisco, July/August, 2009. Drs. David Gandara and
David Jablons are the Conference co-chairs.
The 14th World Lung Cancer conference will be held in
Amsterdam, The Netherlands, July 2–7, 2011. Dr. Pieter
Postmus is the Conference chairman. ICS (International Con-
ference Service), Vancouver, Canada has been chosen to
arrange the coming World Conference 2007, 2009, and 2011.
The new IASLC Journal ‘‘Journal of Thoracic Oncol-
ogy’’ started January 1, 2006 and published 9 issues in 2006.
It is planned to publish 12 issues in 2007. Dr. James Jett is the
Editor of the JTO and has seen the JTO off to a very
successful start.
In 2002 Workshops, Symposia and Educational meet-
ings have been arranged in Belgium, Italy, Austria, India and
Taiwan.
In 2003 Workshops, Symposia and Educational meet-
ings have been arranged in Lithuania, China and Spain.
In 2004 IASLC arranged eight workshops, symposia and
educational meetings in Portugal, US, Switzerland, Thailand,
Brazil, Poland and Germany.
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In 2005 IASLC arranged eight workshops, symposia
and educational meetings in the UK, Japan, India, Indonesia,
Russia, China, Turkey and US.
In 2006 the IASLC arranged 11 workshops in Ireland,
US, Mexico, Czech Republic, Australia, Italy, China, Turkey
and Italy.
In 2007 the IASLC arranged 5 workshops in Ireland,
Italy, US, Turkey, Spain and Austria.
In 2008 two new initiatives will begin. In April: IASLC
and ESMO will arrange 1st European Lung Cancer Confer-
ence in Geneva, Switzerland and in November IASLC,
ASTRO, ASCO and University of Chicago will arrange the
2008 Multidisciplinary Symposium in Thoracic Oncology
in Chicago. Seven workshops in US, Thailand, Switzerland, UK,
Chile and India are planned to be sponsored by IASLC.
The European Society for
Medical Oncology (ESMO)
Founded in 1975 as the Socie´te´ de Me´dicine Interne
Cance´rologique, ESMO took on its present name in 1980,
when it transformed into a pan-European organization that
established itself as a highly respected institution in the field
of oncology. ESMO is the leading European professional
society of medical oncologists, welcomes other related spe-
cialties and has a worldwide membership from over 100
countries. ESMO’s flagship journal, Annals of Oncology,
ranks among the top five clinical oncology journals.
The major focus of all ESMO activities is to improve
cancer prevention and early diagnosis of cancer, as well as
diagnosis, treatment and follow-up care of cancer patients. In
keeping with its mission to embrace patients’ needs, an open
dialogue between patients and physicians has led to the
forging of a patient-physician partnership, to which patients
bring their needs and direct experiences, while physicians
contribute with evidence-based science, in a united effort to
improve healthcare services throughout Europe.
Current developments in oncology indicate the need for
treatment by multidisciplinary teams. To this end, ESMO
offers multidisciplinary programs which foster collaboration
between different disciplines within the Society, such as
medical oncology, radiation oncology, surgical oncology,
pediatric oncology, basic research, oncology pharmacy and
oncology nursing.
ESMO’s multidisciplinary vision has also led to the
forging of strategic partnerships with the other oncology
societies, associations in specific fields and cancer organiza-
tions both in Europe and around the world. ESMO is a
competent, credible partner and consulting Society that works
with numerous organizations, including the European Medi-
cines Agency (EMEA), the European Union (EU) and the
World Health Organization (WHO). ESMO has also actively
been strengthening working relationships with some of the
major national and regional oncology societies around the
world with initiatives such as reciprocal membership, joint
projects and exchange programs.
As part of its global vision and strategy ESMO has
become more active in politics by opening an office in
Brussels. Contributing to the development, funding and po-
sitioning of oncology at the European level is one of ESMO’s
ambitions. Taking care of the future of ESMO members and
patients implies that the Society takes action to raise political
awareness on issues that affect the constantly evolving envi-
ronment of oncology.
ESMO addresses global inequalities in cancer care
through statistical analysis of data concerning the discrepan-
cies in the prerequisites for the practice of oncology in
Europe and developing countries. The summary reports from
this data analysis will help identify necessary improvements
in the infrastructure of those countries that have less than
optimal healthcare systems. They will indicate how to face
the challenge of reducing disparities in the quality of care
available to patients residing in different European countries.
They will also provide further evidence of the need to
recognize medical oncology as an independent specialty
throughout Europe and globally.
Standardized training in medical oncology, based on a
solid background in internal medicine, has been defined in the
Recommendations for a Global Core Curriculum in Medical
Oncology, produced by ESMO in joint collaboration with the
American Society of Clinical Oncology (ASCO). Another
ESMO-ASCO joint publication is the Consensus Statement
on Quality Cancer Care, published in 2006, which outlines
the basic needs and rights of cancer patients to the highest
level of care.
Information, knowledge, and experience combine to
form the backbone of excellence in clinical practice. To this
end ESMO is a platform, offering a wide range of educational
and scientific tools:
Y ESMO Congresses focus on both state-of-the-art edu-
cational sessions and the most recent developments in
oncology research and technology.
Y ESMO Conference Lugano (ECLU) provides a com-
prehensive overview of state-of-the-art oncology for
major cancer types and special interactive sessions that
focus on the needs of young oncologists.
Y ESMO International Symposia (EIS) concentrate on
multidisciplinary approaches to specific fields of oncol-
ogy.
Y ESMO Joint Meetings co-produced organ or disease-
based meetings with other prominent oncology organi-
zations
Y ESMO Partnership Meetings collaborate with oncol-
ogy societies in meetings on topics such as translational
research, targeted therapies, prevention and organ-based
tumors.
Y The ESMO Examination in medical oncology certifies
medical oncologists and is required to practice medical
oncology or be a full member of medical oncology
societies in several European countries.
Y ESMO accredits and supports educational courses, vir-
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tual meetings and Internet-based projects, thereby ex-
panding the ESMO global network.
Y ESMO, together with the Organization of European
Cancer Institutes (OECI), seeks to identify the necessary
criteria for medical oncology departments in compre-
hensive cancer centers.
Y Following the publication of the ESMO Policy on
Palliative and Supportive Care, the Society now ac-
credits ‘Designated Centers of Integrated Oncology and
Palliative Care’ that meet a comprehensive list of crite-
ria and are capable of providing specific training in this
important aspect of patient care.
Y ESMO Clinical Recommendations assess diagnosis
and treatment of various cancers. They are intended as
guidelines for clinical practice and prerequisites for
basic healthcare services.
Y For young oncologists, ESMO offers a career develop-
ment program of fellowships, translational research unit
visits, masterclasses, special educational activities, on-
cology handbooks - and much more.
Y ESMO awards an ever increasing number of grants and
fellowships with the aim of providing scholarships to
exceptional, young oncologists.
Since 2004, the ESMO Foundation has been support-
ing ESMO’s educational activities, ranging from specific
training of young talented people to educational programs of
the highest quality in cancer care and prevention, as well as
activities in translational and clinical research.
The great strides and improvements that are on the
horizon bring with them the need to transform a wholly
scientifically-oriented organization into a Society that is will-
ing and able to face the multifaceted aspects of cancer care
and research. As the voice and driving force of medical
oncology in Europe, ESMO is eager to continue to expand its
role in multidisciplinary oncology, in order to meet the
challenges that lie ahead.
More information on ESMO and its activities is avail-
able at www.esmo.org
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Welcome to the 1st European Lung Cancer Conference
More than 30 years after the foundation of the European
Society for Medical Oncology (ESMO) and the Interna-
tional Association for the Study of Lung Cancer (IASLC),
the two societies have joined forces to hold biennial
meetings presenting the cutting edge of clinical and basic
research in a multidisciplinary scientific event. It is with
great pleasure, therefore, that we welcome you all to the
first of these jointly-organized European Lung Cancer
Conferences.
This is a critical moment in lung cancer, both in disease
prevention and disease management. Pharmacogenomic re-
search is advancing at a great pace and novel findings are
coming to light. New approaches in early detection and
multidisciplinary approaches are being discovered. Radiation
oncology is experiencing a technological revolution. Molec-
ular biology has surfaced as a key to understanding many
diseases, ranging from obesity and diabetes to Alzheimer’s
and cancer. In addition, the tremendous amount of infor-
mation now electronically available has had a great impact
on our work. All of these advances invite sober reflection
on key questions. What hurdles must the medical oncolo-
gist, radiation oncologist, surgeon and pulmonologist over-
come in daily practice and in clinical trials – not to
mention those faced by radiologists, pathologists and oth-
ers involved in the management of lung cancer patients?
What are the opportunities and weaknesses facing us at
this juncture?
On the one hand, we have a unique opportunity to use
modern technological advances to capture the overwhelming
data reported in the literature every day, and to apply these
findings almost immediately to our translational research in
order to provide personalized care for our patients. On the
other hand, however, how many physicians are able to find
time in their daily schedule to dedicate the necessary attention
to reading all the information available – often in journals
with a scope beyond observations from clinical trials – in
order to understand the new biological and clinical develop-
ments and apply them in daily practice?
One of the major early controversies in lung cancer
patient care was the debate on the role of chemotherapy
versus best supportive care. Since then, we have witnessed
great advances that have enabled us to increase cancer pre-
vention, improve patient quality of life and develop better
treatments, especially with combined strategies. However, at
the same time, the crucial questions have become more
complicated and answers more difficult to find. We hope that
this first European Lung Cancer Conference will help us
move forward in our search for answers to unsolved problems
and contribute to the improvement of patient care through
better communication among all the specialists involved. We
are now in a position to offer personalized patient assessment
and care. It’s time to take that crucial step.
Franc¸oise Mornex and Rafael Rosell
Scientific Committee Co-Chairs
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